These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8962138)

  • 21. Production and characterization of a new antibody specific for the mutant EGF receptor, EGFRvIII, in Camelus bactrianus.
    Omidfar K; Rasaee MJ; Modjtahedi H; Forouzandeh M; Taghikhani M; Bakhtiari A; Paknejad M; Kashanian S
    Tumour Biol; 2004; 25(4):179-87. PubMed ID: 15557755
    [TBL] [Abstract][Full Text] [Related]  

  • 22. AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma.
    Hamblett KJ; Kozlosky CJ; Siu S; Chang WS; Liu H; Foltz IN; Trueblood ES; Meininger D; Arora T; Twomey B; Vonderfecht SL; Chen Q; Hill JS; Fanslow WC
    Mol Cancer Ther; 2015 Jul; 14(7):1614-24. PubMed ID: 25931519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Construction of a phage antibody library and screening of anti-epidermal growth factor receptor variant III single chain antibody].
    Han DG; Duan XY; Guo YM; Zhou Q; Wang QY; Yang GX
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jan; 30(1):25-9. PubMed ID: 20117977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA' suppresses growth of a highly metastatic pancreatic carcinoma cell line.
    Bruell D; Stöcker M; Huhn M; Redding N; Küpper M; Schumacher P; Paetz A; Bruns CJ; Haisma HJ; Fischer R; Finnern R; Barth S
    Int J Oncol; 2003 Oct; 23(4):1179-86. PubMed ID: 12964002
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Specific killing of HIV-infected lymphocytes by a recombinant immunotoxin directed against the HIV-1 envelope glycoprotein.
    Bera TK; Kennedy PE; Berger EA; Barbas CF; Pastan I
    Mol Med; 1998 Jun; 4(6):384-91. PubMed ID: 10780881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Generation of humanized single-chain fragment variable immunotherapeutic against EGFR variant III using baculovirus expression system and in vitro validation.
    Xavier S; Gopi Mohan C; Nair S; Menon KN; Vijayachandran LS
    Int J Biol Macromol; 2019 Mar; 124():17-24. PubMed ID: 30471391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Production of a novel camel single-domain antibody specific for the type III mutant EGFR.
    Omidfar K; Rasaee MJ; Modjtahedi H; Forouzandeh M; Taghikhani M; Golmakani N
    Tumour Biol; 2004; 25(5-6):296-305. PubMed ID: 15627895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phage display-based on-slide selection of tumor-specific antibodies on formalin-fixed paraffin-embedded human tissue biopsies.
    Ten Haaf A; Pscherer S; Fries K; Barth S; Gattenlöhner S; Tur MK
    Immunol Lett; 2015 Aug; 166(2):65-78. PubMed ID: 26045318
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EGFRvIII as a promising target for antibody-based brain tumor therapy.
    Kuan CT; Wikstrand CJ; Bigner DD
    Brain Tumor Pathol; 2000; 17(2):71-8. PubMed ID: 11210174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trial.
    Chandramohan V; Pegram CN; Piao H; Szafranski SE; Kuan CT; Pastan IH; Bigner DD
    Appl Microbiol Biotechnol; 2017 Apr; 101(7):2747-2766. PubMed ID: 28013405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selection and characterization of human anti-MAGE-A1 scFv and immunotoxin.
    Lin H; Mao Y; Zhang DW; Li H; Qiu JR; Zhu J; Chen RJ
    Anticancer Agents Med Chem; 2013 Oct; 13(8):1259-66. PubMed ID: 23343082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cloning and cytotoxicity of a human pancreatic RNase immunofusion.
    Zewe M; Rybak SM; Dübel S; Coy JF; Welschof M; Newton DL; Little M
    Immunotechnology; 1997 Jun; 3(2):127-36. PubMed ID: 9237097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
    Reiter Y; Pai LH; Brinkmann U; Wang QC; Pastan I
    Cancer Res; 1994 May; 54(10):2714-8. PubMed ID: 8168102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Production of a human single-chain variable fragment antibody against esophageal carcinoma.
    Xu MY; Xu XH; Chen GZ; Deng XL; Li J; Yu XJ; Chen MZ
    World J Gastroenterol; 2004 Sep; 10(18):2619-23. PubMed ID: 15309706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new scfv-based recombinant immunotoxin against EPHA2-overexpressing breast cancer cells; High in vitro anti-cancer potency.
    Rezaie E; Amani J; Bidmeshki Pour A; Mahmoodzadeh Hosseini H
    Eur J Pharmacol; 2020 Mar; 870():172912. PubMed ID: 31926992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel EGFR-specific recombinant ricin-panitumumab (scFv) immunotoxin against breast and colorectal cancer cell lines; in silico and in vitro analyses.
    Naemi AA; Salmanian AH; Noormohammadi Z; Amani J
    Eur J Pharmacol; 2023 Sep; 955():175894. PubMed ID: 37429519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Kinetic analysis of novel mono- and multivalent VHH-fragments and their application for molecular imaging of brain tumours.
    Iqbal U; Trojahn U; Albaghdadi H; Zhang J; O'Connor-McCourt M; Stanimirovic D; Tomanek B; Sutherland G; Abulrob A
    Br J Pharmacol; 2010 Jun; 160(4):1016-28. PubMed ID: 20590596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and construction of scFv-PE35KDEL as a novel immunotoxin against human epidermal growth factor receptor 2 for cancer therapy.
    Shariaty Vaziri Z; Shafiee F; Akbari V
    Biotechnol Lett; 2023 Apr; 45(4):537-550. PubMed ID: 36807722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning.
    Klimka A; Matthey B; Roovers RC; Barth S; Arends JW; Engert A; Hoogenboom HR
    Br J Cancer; 2000 Jul; 83(2):252-60. PubMed ID: 10901379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.
    Han J; Chu J; Keung Chan W; Zhang J; Wang Y; Cohen JB; Victor A; Meisen WH; Kim SH; Grandi P; Wang QE; He X; Nakano I; Chiocca EA; Glorioso Iii JC; Kaur B; Caligiuri MA; Yu J
    Sci Rep; 2015 Jul; 5():11483. PubMed ID: 26155832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.